Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRAME: Defactinib and VS-6766 in Advanced Solid Tumours
NCT03875820Phase 1Active, not recruiting
- Sponsor
- The Institute of Cancer Research
- Start
- Dec 2017
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of avutometinib and defactinib in solid tumor, non-small cell lung cancer (NSCLC), Low grade serous ovarian cancer (LGSOC) and 3 more (8 arms), sponsored by The Institute of Cancer Research. Primary endpoints: Maximum Tolerated Dose at 12 months and Adverse Events at 6 months. Started Dec 2017; status: active, not recruiting.
02
Drugs
avutometinibdefactinib
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)Low grade serous ovarian cancer (LGSOC)colorectal cancer (CRC)endometrioid carcinoma
Beyond the preview
Go deeper on NCT03875820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03875820.